BPC-157 and TB-500: the research behind the recovery stack

BPC-157 and TB-500 are sold and discussed together so often that "the recovery stack" has become a single product in many people's minds. The research does not support treating them as one thing, or as proven. This is what has actually been studied, in what, and what the regulators have said.

What they are

BPC-157 is a synthetic chain of 15 amino acids based on a sequence from a protein found in human gastric juice. "BPC" stands for body protection compound. Most of the published research comes from one research group at the University of Zagreb, which has studied it since the early 1990s. See BPC-157 in the library.

TB-500 is a short synthetic fragment of thymosin beta-4, a 43-amino-acid peptide present in most human cells. The FDA describes the fragment as LKKTETQ. Thymosin beta-4 itself has been tested in people; TB-500 as such has not. They are not interchangeable, and results for one do not transfer to the other. See TB-500 and thymosin beta-4.

The animal evidence

A 2025 systematic review in the HSS Journal searched PubMed, Cochrane and Embase for every BPC-157 study relevant to orthopaedic sports medicine. Of 544 articles, 36 met the criteria: 35 were preclinical and one was clinical. In rats and other models, BPC-157 improved functional, structural and biomechanical outcomes after muscle, tendon, ligament and bone injury. The proposed mechanisms include new blood vessel growth, growth factor receptor expression and reduced inflammatory signalling. The review found its half-life in animals was under 30 minutes and found no clinical safety data in humans.

That is a real signal, consistently reported. It is also the stage at which most drug candidates fail. Rodent tendon healing is not human tendon healing, and a literature dominated by one group has not had the independent replication that usually comes before human trials.

The human evidence, all of it

The knee study deserves a closer read, because it is the one most often quoted. It was a chart review at a single private clinic. Of 17 patients, 16 were reached by phone between six months and a year after their injection and asked to rate their pain retrospectively. No validated scoring tool was used, there was no comparison group, and the clinic that reported the results also provided the treatment. The 2025 systematic review summarised the same paper as 7 of 12 patients reporting relief lasting more than six months. It is a reason to run a trial, not evidence that the treatment works.

The IV pilot involved two people, both of whom had received the peptide before. It cannot establish safety in any statistical sense, and its authors called for further studies. A phase 1 trial registered in 2015 (NCT02637284) never posted results.

The hamstring trial is the first properly controlled human test of BPC-157. It is the result worth waiting for.

What the FDA has said

BPC-157 and TB-500 are not FDA-approved drugs for any use. The question that has moved in the last two years is whether compounding pharmacies may make them.

Until April 2026 both sat on the FDA's Category 2 list of bulk substances that may present significant safety risks in compounding. The FDA's stated concerns, which remain on its page, were the risk of immune reactions for some routes of administration, peptide-related impurities, difficulty characterising the active ingredient and, for BPC-157, "no, or only limited, safety-related information" for the proposed routes. For the TB-500 fragment the FDA says it "has not identified any human exposure data."

The FDA's page updated on 22 April 2026 moved both substances, with several other peptides, into a table of nominations "withdrawn by the nominators." The FDA then took BPC-157 and TB-500 to its Pharmacy Compounding Advisory Committee on its own initiative. On 23 July 2026 the committee voted 8 to 6, with one abstention, to recommend each for the 503A bulks list, against the advice of FDA staff. That vote is advisory. As of October 2026 no rule adding either substance to the list has been published. Our PCAC explainer covers what happens next, and peptide policy tracks the docket.

Sport

The World Anti-Doping Agency lists BPC-157 under S0, non-approved substances, and thymosin beta-4 and its derivatives, naming TB-500, under S2. Both are prohibited at all times, in and out of competition. Tested athletes should treat that as the end of the question.

What this adds up to

A large and consistent animal literature, mostly from one group. Three small human reports with no controls. One randomised trial under way. No established human dose for either compound, which is why we do not publish one. And no study, animal or human, that set out to test whether the two together do anything that either does alone; the four patients in the knee review who received both are the entire human dataset on the combination. The stack research guide covers how to think about that gap.

If you are keeping a record

For anyone under a clinician's care with one of these, the useful log is the injury itself: a pain score on the same scale each day, range of motion or a functional test, training load, and anything else that changed in the same weeks. The dose log and training log in Peptide AI keep those on one timeline, and the library grades how much research sits behind each compound.